Abstracts
bone marrow transplantation versus conventional dose chemotherapy for previously untreated patients with aggressive non-Hodgkin's lymphoma at high risk for relapse. METHODS: Costs and patient responses (outcomes) were evaluated for the first 84 patients in this ongoing prospective randomized clinical trial. Data were compiled from November 1995 until May 2001. Patient outcomes were retrieved from the institutional Protocol Data Management System and costs were retrieved from institutional financial and administrative databases. Direct costs included hospital, clinic, pharmacy, and physician costs. Pearson chi square was used to analyze the association between costs and treatment group. RESULTS: Forty-four patients received conventional dose chemotherapy and 40 patients received BMT. The average cost of therapy per patient for conventional dose chemotherapy was $61,515 (range $5,360 to $186,684) and the average cost per patient for BMT was $133,365 (range $11,868 to $431,248). Outcomes were categorized as complete response (n = 36), partial response (n = 35), and other (incomplete to date n = 13). Costs were categorized as low (<$45,000), medium ($45,000-$80,999), medium high ($81,000-$125,999), and high (>$126,000). In the conventional dose chemotherapy group 61.1% of patients had a complete response and 38.9% of patients in the BMT group had a complete response. Costs for conventional dose chemotherapy patients were in the low to medium cost groups, and costs for BMT patients were in the medium-high to high cost groups (chi square = 29.422, d.f. = 3, p < 0.001). CONCLUSIONS: Overall, higher costs were observed in the BMT group, and more complete responses were observed in the conventional dose chemotherapy group. 
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COLLECTION OF INFECTIOUS DISEASE AND ECONOMIC OUTCOMES FOR NON-HODGKIN'S LYMPHOMA AND MULTIPLE MYELOMA PATIENTS ADMITTED FOR INFECTIOUS COMPLICATIONS UTILIZING
OBJECTIVES:
To evaluate infectious disease outcomes and cost of care for lymphoma and myeloma patients admitted for infectious complications. To evaluate a Palm handheld as a tool for prospective data collection utilizing Pendragon Forms software. METHODS: Patients admitted to the Lymphoma/ Myeloma service receiving anti-infective therapy for infectious diseases were followed. Targeted outcomes were collected prospectively during hospitalization and included length of hospitalization (days), adverse events attributed to the anti-infective, febrile days (≥38.3°C),
